Measles Virus Neutralizing Antibodies in Intravenous Immunoglobulins: Is an Increase by Revaccination of Plasma Donors Possible?. (18th August 2017)

• Record Type: Journal Article
• Authors: Modrof, Jens; Tille, Björn; Farcet, Maria R; McVey, John; Schreiner, Jessica A; Borders, Charles M; Gudino, Maria; Fitzgerald, Peter; Simon, Toby L; Kreil, Thomas R
• Is Part Of: Journal of infectious diseases. Volume 216:Number 8(2017:Oct. 15)
• Page Start: 977
• Page End: 980
• Publication Date: 2017-08-18
• Subjects: Primary immunodeficiency -- measles virus antibody titer -- measles vaccination -- intravenous immune globulin -- titer decline -- antibody boost -- FDA regulation 21 CFR 640.104; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jix428
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract : Measles virus antibody levels are declining in plasma for fractionation and in immunoglobulin products manufactured thereof. Revaccination of plasma donors did not result in a significant antibody boost and is therefore not a sustainable measure to increase antibody titers. Abstract: We report a screen of plasma donors confirming that widespread use of childhood measles vaccination since 1963 resulted in a decrease in average measles virus antibody titers among plasma donors, which is reflected in intravenous immunoglobulins (IVIGs). The measles virus antibody titer, however, is a potency requirement for IVIGs, as defined in a Food and Drug Administration regulation. To mitigate the decline in measles virus antibody titers in IVIGs and to ensure consistent product release, revaccination of plasma donors was investigated as a means to boost titers. However, revaccination-induced titer increases were only about 2-fold and short-lived.